Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
"We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."
- "We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive and malignant disease in haematology with an incidence in Europe of approximately 8.8 cases per 100,000 adults per year1.
- ADC Therapeutics' CD19-directed ADC Zynlonta (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.
- Postal address SE-112 76 Stockholm, Sweden
For details on how to contact the Sobi Investor Relations Team, please click here .